RxDoctor Payments Data

Ravi Rao, MD

Internal Medicine · Lafayette, INNPI 1134651110

Payments from drug & device makers

$1,032in general payments, 2019–2025

Across 25 payments — averaging $41.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$255
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$184
  • Edwards Lifesciences$166
  • Abbott$149
  • Pfizer$72
  • Medtronic$59
  • plus $146 from 6 others

What the payments were for

  • Food & beverage$98696%
  • Education$464%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,032 in reported general payments places this provider in the 75th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$139,984
Medicare patients
1,934
Services billed
3,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban108$125,110
EntrestoSacubitril/Valsartan43$77,589
JardianceEmpagliflozin40$50,421
XareltoRivaroxaban18$28,948
FarxigaDapagliflozin Propanediol16$18,847
Metoprolol Succinate188$2,006
Isosorbide Mononitrate ErIsosorbide Mononitrate78$1,122
Ranolazine ErRanolazine21$981
Digoxin40$923
Potassium Chloride20$829
Atorvastatin Calcium65$618
ClopidogrelClopidogrel Bisulfate58$481
Amlodipine Besylate79$372
Metoprolol Tartrate38$361
Carvedilol53$349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$72$125,110108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →